Celularity Inc.: peers
Celularity Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
CytRx Corporation: the market cap on file is more than 60 days old or a last known value (no market-data feed for its exchange yet), so its valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Celularity Inc.base CELU · 🇺🇸 US Percentile in Healthcare Percentile in USA | ABVC BioPharma, Inc. ABVC · 🇺🇸 US Percentile in Healthcare Percentile in USA | BioStem Technologies, Inc. BSEM · 🇺🇸 US Percentile in Healthcare Percentile in USA | CervoMed Inc. CRVO · 🇺🇸 US Percentile in Healthcare Percentile in USA | CEL-SCI Corporation CVM · 🇺🇸 US Percentile in Healthcare Percentile in USA | IGC Pharma, Inc. IGC · 🇺🇸 US Percentile in Healthcare Percentile in USA | CytRx Corporation CYTR · 🇺🇸 US Percentile in Healthcare Percentile in USA | NextCure, Inc. NXTC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $28 MOct 30, 2026 · Market data5th of 8 | $28 MOct 30, 2026 · Market data4th of 8 | $29 MOct 29, 2026 · Market data3rd of 8 | $26 MOct 30, 2026 · Market data6th of 8 | $26 MOct 30, 2026 · Market data7th of 8 | $29 MOct 26, 2026 · Market data2nd of 8 | $26 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one8th of 8 | $30 MOct 30, 2026 · Market data1st of 8 | $28 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $27 MFY2025 · SEC2nd of 4 | $0 MFY2025 · SEC4th of 4 | $47 MFY2025 · SEC1st of 4 | $4 MFY2025 · SEC3rd of 4 | —— | —— | —— | —— | $15 M4 ranked |
| Net income (Higher is better) | $-92 MFY2025 · SEC7th of 7 | $-8 MFY2025 · SEC3rd of 7 | $-7 MFY2025 · SEC2nd of 7 | $-27 MFY2025 · SEC5th of 7 | $-25 MFY2025 · SEC4th of 7 | —— | $-2 MFY2024 · SEC1st of 7 | $-56 MFY2025 · SEC6th of 7 | $-25 M7 ranked |
| Employees (Better neither way: ranked highest first) | 288As on July 2022 · Profile1st of 2 | —— | —— | 15December 31, 2025 · Profile2nd of 2 | —— | —— | —— | —— | 1522 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | -51.0%FY2025 · SEC2nd of 33rd1st | ———— | -31.8%FY2025 · SEC1st of 37th4th | -58.8%FY2025 · SEC3rd of 32nd1st | ———— | ———— | ———— | ———— | -51.0%3 ranked |
| Revenue growth, 3 years a year (Higher is better) | +13.9%FY2025 · SEConly one with it62nd78th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | +13.9%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 24.4%FY2025 · SEC2nd of 212th26th | ———— | 93.6%FY2025 · SEC1st of 295th98th | ———— | ———— | ———— | ———— | ———— | 59.0%2 ranked |
| Operating margin (Higher is better) | -230.9%FY2025 · SEC2nd of 314th5th | ———— | -1.4%FY2025 · SEC1st of 356th38th | -705.5%FY2025 · SEC3rd of 33rd1st | ———— | ———— | ———— | ———— | -230.9%3 ranked |
| Net margin (Higher is better) | -345.5%FY2025 · SEC2nd of 39th3rd | ———— | -13.9%FY2025 · SEC1st of 346th24th | -672.6%FY2025 · SEC3rd of 33rd1st | ———— | ———— | ———— | ———— | -345.5%3 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | 13.9%FY2025 · SEConly one with it78th78th | ———— | ———— | ———— | ———— | ———— | 13.9%— |
| Return on equity (Higher is better) | ———— | -128.2%FY2025 · SEC4th of 519th8th | -16.6%FY2025 · SEC1st of 562nd29th | -93.9%FY2025 · SEC2nd of 526th11th | -176.3%FY2025 · SEC5th of 513th5th | ———— | ———— | -111.2%FY2025 · SEC3rd of 522nd10th | -111.2%5 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | 1.5×price Oct 30, 2026 · Market data4th of 524th39th | 93.5×price Oct 30, 2026 · Market data1st of 594th98th | 0.7×price Oct 29, 2026 · Market data5th of 512th21st | 6.6×price Oct 30, 2026 · Market data3rd of 563rd83rd | ———— | 24.9×price Oct 26, 2026 · Market data2nd of 585th95th | ———— | ———— | 6.6×5 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | 2.5×price Oct 30, 2026 · Market data2nd of 643rd56th | 0.7×price Oct 29, 2026 · Market data6th of 613th13th | 1.4×price Oct 30, 2026 · Market data4th of 629th35th | 1.6×price Oct 30, 2026 · Market data3rd of 633rd40th | 3.9×price Oct 26, 2026 · Market data1st of 659th70th | ———— | 0.9×price Oct 30, 2026 · Market data5th of 616th16th | 1.6×6 ranked |
| Free cash flow yield (Higher is better) | -23.8%price Oct 30, 2026 · Market data4th of 730th13th | -15.0%price Oct 30, 2026 · Market data2nd of 737th17th | 22.8%price Oct 29, 2026 · Market data1st of 798th96th | -48.3%price Oct 30, 2026 · Market data5th of 719th8th | -65.0%price Oct 30, 2026 · Market data6th of 714th5th | -16.8%price Oct 26, 2026 · Market data3rd of 736th16th | ———— | -138.0%price Oct 30, 2026 · Market data7th of 74th1st | -23.8%7 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | 0.0×FY2025 · SEC1st of 25th3rd | ———— | ———— | 0.0×FY2025 · SEC2nd of 212th8th | ———— | ———— | 0.0×2 ranked |
| Interest cover (Higher is better) | ———— | -715.0×FY2025 · SEC2nd of 23rd1st | ———— | ———— | -38.2×FY2025 · SEC1st of 224th11th | ———— | ———— | ———— | -376.6×2 ranked |
| Piotroski F-score (Higher is better) | —— | —— | 5 of 9FY2025 · SEConly one with it | —— | —— | —— | —— | —— | 5.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 4 of 19FY2025 · Scorecard6th of 8 | 2 of 16FY2025 · Scorecard8th of 8 | 9 of 15FY2025 · Scorecard1st of 8 | 3 of 14FY2025 · Scorecard5th of 8 | 3 of 13FY2025 · Scorecard4th of 8 | 2 of 8FY2025 · Scorecard3rd of 8 | 2 of 7FY2024 · Scorecard2nd of 8 | 2 of 14FY2025 · Scorecard7th of 8 | 22% passed8 ranked |
| Valuation checks (Higher is better) | 1 of 5FY2025 · Scorecard5th of 7 | 1 of 5FY2025 · Scorecard5th of 7 | 3 of 5FY2025 · Scorecard1st of 7 | 2 of 5FY2025 · Scorecard2nd of 7 | 1 of 4FY2025 · Scorecard3rd of 7 | 0 of 5FY2025 · Scorecard7th of 7 | —— | 1 of 4FY2025 · Scorecard3rd of 7 | 25% passed7 ranked |
| Growth checks (Higher is better) | 3 of 6FY2025 · Scorecard1st of 7 | 1 of 3FY2025 · Scorecard4th of 7 | 0 of 2FY2025 · Scorecard5th of 7 | 0 of 2FY2025 · Scorecard5th of 7 | 1 of 2FY2025 · Scorecard1st of 7 | —— | 1 of 2FY2024 · Scorecard1st of 7 | 0 of 2FY2025 · Scorecard5th of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | 0 of 4FY2025 · Scorecard2nd of 7 | 0 of 3FY2025 · Scorecard2nd of 7 | 1 of 3FY2025 · Scorecard1st of 7 | 0 of 4FY2025 · Scorecard2nd of 7 | 0 of 3FY2025 · Scorecard2nd of 7 | —— | 0 of 2FY2024 · Scorecard2nd of 7 | 0 of 3FY2025 · Scorecard2nd of 7 | 0% passed7 ranked |
| Financial health checks (Higher is better) | 0 of 3FY2025 · Scorecard6th of 8 | 0 of 4FY2025 · Scorecard6th of 8 | 4 of 4FY2025 · Scorecard1st of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 1 of 3FY2025 · Scorecard4th of 8 | 2 of 3FY2025 · Scorecard2nd of 8 | 0 of 2FY2024 · Scorecard6th of 8 | 1 of 2FY2025 · Scorecard3rd of 8 | 33% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard3rd of 6 | 0 of 1FY2025 · Scorecard3rd of 6 | 1 of 1FY2025 · Scorecard1st of 6 | —— | 0 of 1FY2025 · Scorecard3rd of 6 | —— | 1 of 1FY2024 · Scorecard1st of 6 | 0 of 3FY2025 · Scorecard3rd of 6 | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 6.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | 4.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 9.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 8.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 7 | 11.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 5.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | —— | 67.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 8.8%7 ranked |
| Institutions holding (Better neither way: ranked highest first) | 332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 152026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 7 | 262026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 7 | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 7 | 442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 7 | 292026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 7 | —— | 332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 7 | 337 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -0.7 pp2026-Q2 against 2026-Q1 · 13F4th of 6 | +0.9 pp2026-Q2 against 2026-Q1 · 13F2nd of 6 | —— | -7.5 pp2026-Q2 against 2026-Q1 · 13F5th of 6 | +2.6 pp2026-Q2 against 2026-Q1 · 13F1st of 6 | +0.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 6 | —— | -22.1 pp2026-Q2 against 2026-Q1 · 13F6th of 6 | -0.0 pp6 ranked |
| Dividends | |||||||||
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | —— | $0.00FY2025 · SEConly one with it | $0.00— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Celularity Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ABVC BioPharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; BioStem Technologies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CervoMed Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CEL-SCI Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; IGC Pharma, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; CytRx Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NextCure, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Celularity Inc. | -230.9%FY2025 | 14th percentile in Healthcaremedian -7.7%, 674 companies | 5th percentile in USAmedian 3.5%, 2,594 companies |
| ABVC BioPharma, Inc. | — | — | — |
| BioStem Technologies, Inc. | -1.4%FY2025 | 56th percentile in Healthcaremedian -7.7%, 674 companies | 38th percentile in USAmedian 3.5%, 2,594 companies |
| CervoMed Inc. | -705.5%FY2025 | 3rd percentile in Healthcaremedian -7.7%, 674 companies | 1st percentile in USAmedian 3.5%, 2,594 companies |
| CEL-SCI Corporation | — | — | — |
| IGC Pharma, Inc. | — | — | — |
| CytRx Corporation | — | — | — |
| NextCure, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Celularity Inc. | ABVC BioPharma, Inc. | BioStem Technologies, Inc. | CervoMed Inc. | CEL-SCI Corporation | IGC Pharma, Inc. | CytRx Corporation | NextCure, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $27 MSEC2nd | $0 MSEC4th | $47 MSEC1st | $4 MSEC3rd | — | — | — | — |
| 2024 | $54 MSEC2nd | $1 MSEC5th | $70 MSEC1st | $10 MSEC3rd | — | $1 MSEC4th | — | — |
| 2023 | $23 MSEC1st | $0 MSEC4th | — | $7 MSEC2nd | — | $1 MSEC3rd | — | — |
| 2022 | $18 MSEC1st | $1 MSEC2nd | — | — | — | $1 MSEC3rd | — | — |
| 2021 | $21 MSEC1st | $0 MSEC3rd | — | — | — | $0 MSEC2nd | — | — |
| 2020 | $14 MSEC2nd | $0 MSEC4th | — | — | — | $1 MSEC3rd | — | $22 MSEC1st |
| 2019 | — | $1 MSEC3rd | — | — | — | $4 MSEC2nd | — | $6 MSEC1st |
| 2018 | — | — | — | — | — | $5 MSEC1st | $0 MSEC2nd | — |
| 2017 | — | — | — | — | — | $2 MSEC1st | $0 MSEC2nd | — |
| 2016 | — | — | — | — | — | $1 MSEC | — | — |
| 2015 | — | — | — | — | — | $6 MSEC | — | — |
| 2014 | — | — | — | — | $0 MSEC2nd | $8 MSEC1st | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Celularity Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- ABVC BioPharma, Inc.ABVC · 🇺🇸 USASame industry: Biotechnology · Similar size: $28 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $28 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- BioStem Technologies, Inc.BSEM · 🇺🇸 USASame industry: Biotechnology · Similar size: $29 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $29 M (Oct 29, 2026) · revenue $47 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- CervoMed Inc.CRVO · 🇺🇸 USASame industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26 M (Oct 30, 2026) · revenue $4 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- CEL-SCI CorporationCVM · 🇺🇸 USASame industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- IGC Pharma, Inc.IGC · 🇺🇸 USASame industry: Biotechnology · Similar size: $29 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $29 M (Oct 26, 2026) · revenue $1 M (year to March 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- CytRx CorporationCYTR · 🇺🇸 USASame industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26 M (last known, Jan 7, 2022)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- NextCure, Inc.NXTC · 🇺🇸 USASame industry: Biotechnology · Similar size: $30 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $30 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Atossa GeneticsATOS · 🇺🇸 USASame industry: Biotechnology · Similar size: $26 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $26 M (Oct 14, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)+ Add
- Metagenomi Therapeutics, Inc.MGX · 🇺🇸 USASame industry: Biotechnology · Similar size: $30 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $30 M (Oct 28, 2026) · revenue $25 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Protokinetix IncorporatedPKTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $25 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $25 M (last known, Jan 7, 2022)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Agentix Corp.AGTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $31 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $31 M (last known, Jan 7, 2022)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- AEON Biopharma, Inc.AEON · 🇺🇸 USASame industry: Biotechnology · Similar size: $24 M market cap against $28 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $24 M (Oct 30, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.